- Home
- PASG vs LTRN Comparison
PASG vs LTRN Comparison
Compare PASG & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PASG | LTRN |
|---|---|---|
| Founded | 2017 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.3M | 49.9M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PASG | LTRN |
|---|---|---|
| Price | $10.00 | $3.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $34.50 | $25.00 |
| AVG Volume (30 Days) | 44.2K | ★ 70.7K |
| Earning Date | 11-10-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.12 | $2.55 |
| 52 Week High | $20.20 | $6.12 |
Technical Indicators
Market Signals| Indicator | PASG | LTRN |
|---|---|---|
| Relative Strength Index (RSI) | 58.34 | 47.80 |
| Support Level | $8.23 | $3.72 |
| Resistance Level | $10.71 | $3.98 |
| Average True Range (ATR) | 0.89 | 0.27 |
| MACD | 0.16 | 0.04 |
| Stochastic Oscillator | 70.67 | 48.72 |
Price Performance
Historical ComparisonAbout PASG Passage Bio Inc.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.